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Stress ulcer prophylaxis in critically ill
patients
Stress-related mucosal damage (SRMD) is an erosive
gastritis of unclear pathophysiology, which can occur rapidly
after a severe insult such as trauma, surgery, sepsis or burns.
SRMD is apparent in 75–100% of critically ill patients within
24 hours of admission to an intensive care unit (ICU) [1,2].
Clinically important bleeding, defined as macroscopic
bleeding resulting in hemodynamic instability or the need for
red blood cell transfusion, occurs as a result of SRMD in
about 3.5% of ICU patients who are mechanically ventilated
for 48 hours or more [3]. Along with mechanical ventilation,
risk factors for clinically important bleeding from SRMD
include coagulopathy, shock, severe burns, a history of
gastrointestinal (GI) ulceration, and multiple organ failure
[4,5]. Bleeding is associated with a 20–30% increase in
absolute risk of mortality, and with an increase of 1–4 in
relative risk [3]. In addition, it increases the demand on limited
blood stocks and extends the length of ICU stay by about
4–8 days [3], thereby adding to overall management costs.
To avert these consequences, prophylaxis has been
recommended for all ICU patients at high risk of SRMD [4,5].
Stress ulcer prophylaxis is included in the care bundle for
critically ill patients on mechanical ventilation recommended
by the Institute for Healthcare Improvement and adopted by
the National Health Service Modernization agency in the UK
[6]. The Surviving Sepsis Campaign, an international initiative
founded by the European Society of Intensive Care Medicine,
the Society of Critical Care Medicine and the International
Sepsis Forum, has also recommended that prophylaxis be a
part of critical care [7]. Specific risk factors for SRMD
include: mechanical ventilation (more than 48 hours),
coagulopathy, neurosurgery, any kind of shock, respiratory
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Abstract
Prophylaxis is routinely provided for critically ill patients admitted to intensive care units (ICUs) who are
at high risk for stress-related mucosal damage (SRMD), an erosive process of the gastroduodenum
associated with abnormally high physiological demands. Traditionally, treatment options have included
sucralfate, antacids and histamine H2 receptor antagonists (H2RAs). The H2RAs are currently the most
widely used agents in prophylactic acid suppression; however, proton pump inhibitors (PPIs) have
recently replaced H2RAs in the treatment of many acid-related conditions. PPIs achieve a more rapid
and sustained increase in gastric pH and are not associated with the rapid tachyphylaxis seen with
H2RAs. As a result, and after the introduction of intravenous formulations, PPIs are beginning to be
used for the prophylaxis of SRMD in critically ill adults. The high prevalence of renal and hepatic
impairment among the ICU population, as well as the need for multiple drug therapy in many patients,
means that pharmacokinetic characteristics and the potential for drug interactions may be important
considerations in the choice of prophylactic agent. This review seeks to present the pharmacological
evidence that may inform decision-making about the prescription of drugs for prophylaxis of SRMD.
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failure, sepsis, polytrauma, tetraplegia, severe burns (more
than 30%) and multiple organ failure [4,5]. Patients in the
ICU with a history of gastric or duodenal ulceration, or with
liver cirrhosis or acute renal failure, may also benefit from
prophylactic measures [4,5].
Although there was once concern that prophylaxis for SRMD
by means of gastric alkalinisation might independently increase
the risk of nosocomial pneumonia, this seems to have been
unfounded. No significant difference in the rate of pneumonia
was seen among 1200 patients randomised to treatment with
intravenous (IV) ranitidine (19.1%) or intragastric sucralfate
(16.2%), the latter having little effect on gastric pH [8]. In
practice, the risk of ventilator-associated pneumonia can be
reduced in any event through the adoption of the fundamental
measures included in the recommended care bundle, such as
elevating the head of the patient’s bed to 30° or higher [6].
Method
Few clinical trials have investigated the use of a proton pump
inhibitor (PPI) in the prophylaxis of stress ulcer in critically ill
patients. In the absence of robust data allowing a systematic
review, the points made in this paper are based on a narrative
review of the literature concerning the pharmacology of the
PPIs and their use in other indications. Literature searches
were undertaken on PubMed Medline, using broad terms
such as ‘stress ulcer’ ‘critically ill’, ‘intensive care’, ‘gastric
acid’, ‘proton pump inhibitor’ and ‘histamine antagonist’, as
well as specific drug names, to identify relevant, peer-
reviewed papers. Manual searching was conducted within
the reference lists of the primary papers identified, and
among relevant conference abstracts.
Pharmacokinetic considerations
The pharmacokinetic characteristics of a drug are particularly
important in prescribing in critical care, because of the
prevalence of organ dysfunction. In a prospective study to
assess the incidence of organ dysfunction or failure among
1449 patients admitted to 40 ICUs, it was found that 40%
had at least some degree of renal impairment, and 19% had
some degree of hepatic impairment [9]. Among ICU patients
with sepsis (one of the patient groups most at risk for
SRMD), these proportions were even higher, with 60% of
1643 patients found to have renal impairment and 73%
hepatic impairment [10]. However, it is possible that even
these figures might not accurately reflect the high prevalence
of renal and hepatic dysfunction among the ICU population.
Thus, a pharmacokinetic profile that obviates the need for
dose adjustment in patients with renal or hepatic dysfunction
is an important characteristic for a drug used routinely in
critical care. Also important is the potential for drug
interactions, and this is dealt with below.
Current treatment options
Prophylaxis for SRMD essentially involves either protecting
the gastric mucosa or increasing the intragastric pH. The
principal means of directly protecting the gastric mucosa is
the use of sucralfate. Although the potential protective effect
of enteral nutrition on the gastric mucosa means that it should
be considered as an adjunct to pharmacological prophylaxis
in appropriate cases, there is currently no evidence that
enteral nutrition alone is sufficient to reduce the risk of stress-
related bleeding [11].
Traditionally, the options for elevating intragastric pH have
been antacids and histamine H2 receptor antagonists
(H2RAs) [5]. An early study in ICU patients demonstrated that
maintaining the gastric pH above 3.5 significantly reduced
the risk of upper gastrointestinal (GI) bleeding [12]. It is now
generally accepted that the aim of acid suppression in the
prophylaxis of SRMD is to maintain gastric pH above 4, a
value at which there is a significant decrease in back-
diffusible hydrogen ions and inactivation of pepsin [5]. The
time taken to elevate pH is also important, because
increasing the percentage of time at which pH is greater than
4 is associated with a lower incidence of lesions and
subsequent haemorrhagic complications [13].
Sucralfate, the antacids, and the H2RAs have each been
shown to be effective in reducing the risk of overt and
clinically significant bleeding compared with placebo [5,14].
H2RAs are currently the most widely used agents [15].
The limitations of current therapies
Sucralfate
Sucralfate must be administered intragastrically and is
therefore unsuitable for patients in whom a gastric tube
cannot be placed. Administration of sucralfate has been
associated with acid aspiration and subsequent aspiration
pneumonia [16]. Sucralfate is a basic aluminium salt of
sucrose octasulphate and there is doubt over its effective-
ness in conditions of elevated pH [16], for example after
enteral feeding or the administration of an acid-suppressing
agent. Adverse events associated with sucralfate include
constipation, feeding-tube occlusion, bezoars, aluminium
accumulation and hypophosphataemia [4,5,17,18]. Additionally,
caution is required in patients with renal impairment because
of the risk of aluminium toxicity [4,19–22]. Furthermore, drug
binding with sucralfate can reduce the effects of warfarin,
phenytoin, digoxin, quinidine [23,24] and the fluoroquino-
lones ciprofloxacin and norfloxacin [25].
Antacids
Antacids are not widely administered routinely nowadays, with
an exception being before Caesarean section. Like sucralfate,
antacids need to be administered intragastrically. They must be
administered at intervals of 1–2 hours and the dose depends
on intragastric pH, requiring frequent pH monitoring and dose
titration. The potential adverse effects associated with antacids
include aluminium toxicity if an aluminium-containing antacid is
used, electrolyte disturbances and diarrhoea [26,27]; feeding-
tube occlusions are also a potential drawback.47
Histamine H2 receptor antagonists
Although placebo-controlled clinical studies demonstrate that
the H2RAs significantly reduce the risk of overt and clinically
significant GI bleeding in critically ill patients [5,8], these
agents have a number of limitations concerning efficacy.
Perhaps the most significant is the potential for tachyphylaxis
to develop during prolonged IV dosing, which means that
gastric pH is not reliably maintained above 4 [13,28–30]. This
is believed to result from an increase in the release of
endogenous histamine, which competes for the receptor sites
with the antagonist [31]. Tolerance can occur within 42 hours
[30] and pH control can deteriorate quickly despite the use of
a high-dose regimen [32]. In addition, H2RAs do not inhibit
vagally induced acid secretion, making them less efficacious in
neurosurgical or head trauma patients with hyperacidity.
The most common adverse effects associated with H2RAs
include headaches, dizziness, diarrhoea, nausea and
constipation [1]. More rarely, H2RAs can also cause serious
adverse effects such as thrombocytopenia [33], changes in
liver function, and interstitial nephritis [34]. All H2RAs are
eliminated renally to some extent, and their clearance is
therefore appreciably reduced in patients with renal failure,
mandating dose adjustment in such patients [35].
With respect to drug interactions, the H2RAs cimetidine and
ranitidine have the drawback of a potent inhibitory effect on
the cytochrome oxidase enzyme system [16]. Cimetidine
increases the plasma levels of theophylline, warfarin,
metronidazole, imipramine, triazolam, diazepam, phenytoin,
lidocaine, quinidine, nifedipine and propranolol [36–42].
Cimetidine must therefore be used with caution in patients
treated concomitantly with other medications [43,44].
Ranitidine has a lower potential for clinically significant drug
interactions but has been shown to potentiate the sedative
effect of midazolam and increase plasma levels of
theophylline and phenytoin [45–47]. The newer H2RAs,
nizatidine and famotidine, seem not to be associated with
significant drug interactions [48–50].
The use of PPIs for acid suppression in
critical illness
PPIs, such as esomeprazole, lansoprazole, omeprazole,
pantoprazole and rabeprazole, are the most effective agents
for suppressing gastric acidity; the superior efficacy of a PPI
over an H2RA has been demonstrated in patients with peptic
ulcer disease, gastroesophageal reflux disease, GI damage
caused by non-steroidal anti-inflammatory drugs, and
Zollinger–Ellison syndrome [51–58]. In general GI practice,
PPIs are now considered the drug of choice in the
management of most acid-related GI disorders [1]. No
tachyphylactic phenomena have been reported in patients
taking PPIs [13,28], resulting in more predictable and
sustained pH control than with H2RAs [14,29]. Adverse
effects from PPIs are uncommon, but can include headaches,
diarrhoea, nausea, constipation and pruritis [59–61].
The possibility of achieving a more profound and sustained
acid suppression provides a rationale for the use of the PPIs
in preference to H2RAs in prophylaxis for SRMD, although
few studies have evaluated PPIs specifically for stress ulcer
prophylaxis. However, most such studies have demonstrated
clearly that enteral or IV administration of a PPI elevates
intragastric pH and maintains a pH of at least 4 [62–72].
Furthermore, comparative studies have shown PPIs to be
more effective than H2RAs for elevating intragastric pH
[13,28,65,66], and two have shown enteral omeprazole to be
more effective than ranitidine in reducing the risk of SRMD-
associated bleeding [64,69].
Which PPI for stress ulcer prophylaxis?
The ideal agent for stress ulcer prophylaxis should be
effective in reducing the risk of ulceration, with a low potential
for adverse effects and drug interactions, should have
pharmacokinetic characteristics that facilitate its use in
patients with organ dysfunction, and should be cost effective,
taking into account not only the cost of acquisition but the
costs of administration and monitoring. How the available
agents compare with regard to this ideal is outlined in Table 1.
Use in organ dysfunction
Given the prevalence of organ dysfunction or failure among
ICU patients, ease of drug handling is an important factor in
the choice of prophylaxis for SRMD. Because it exhibits dose
linearity [73] and does not accumulate in the body after
repeat administration, pantoprazole can be used without
dose adjustment in elderly patients and in those with renal
impairment or failure, or moderate hepatic impairment
[73–76]. Because of their nonlinearity of dose [77],
omeprazole and lansoprazole do not afford this same
independence of dose.
Drug interactions
The metabolism of all PPIs initially involves the hepatic
cytochrome P450 and isoenzymes 2C19 and CYP3A4
[76,78]. However, individual PPIs differ considerably in their
potential for clinically significant drug interactions [78].
Omeprazole, for example, reduces the clearance of carba-
mazepine and diazepam, and also that of phenytoin, which
has a narrow therapeutic index [79]. Interaction studies with
lanzoprazole have demonstrated a significant decrease in the
elimination half-life [80] and the area under curve [81] of
concomitant theophylline.
After the initial CYP450-dependent phase of its metabolism,
pantoprazole is further metabolised by non-saturable phase II
reactions [73]. This results in a much lower potential for
pantoprazole to interact with the cytochrome P450 system
[77]. Pantoprazole has shown no clinically significant drug
interactions in formal studies investigating a wide variety of
concomitant drugs, including carbamazepine, cisapride,
diazepam, diclofenac, digoxin, glibenclamide, naproxen,
nifedipine, theophylline and warfarin [76,77].
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Administration options
The availability of an IV formulation is important for credible
stress ulcer prophylaxis, because enteral administration might
not always be possible in critically ill patients. An IV
formulation of pantoprazole is available worldwide, and IV
preparations of omeprazole and esomeprazole are available in
many countries. There is currently no IV formulation of
lansoprazole, but it is available as a syrup suspension, which
can be administered nasogastrically. Omeprazole can be
prepared for nasogastric administration by mixing crushed
tablets with a vehicle such as apple juice.
Summary
As the most effective antisecretory agents, PPIs undoubtedly
have the potential to benefit ICU patients at risk for SRMD.
However, further clinical studies in the ICU setting are
required to confirm this expectation. The link between the
superior acid-suppressive efficacy of the PPIs and a reduced
risk of SRMD versus H2RAs has been demonstrated in only a
limited number of clinical trials, and this evidence base needs
to be extended. As far as their cost effectiveness is
concerned, PPIs might be expected to offer potential cost
savings compared with no treatment or treatment with
traditional agents, through reducing the incidence of stress-
related bleeding, costs associated with red cell transfusions
and avoiding the consequent extension of ICU stay. In
addition, both the option of continuous infusion of IV
formulations and the lack of any need for pH monitoring with
the PPIs have the potential to save costs associated with
nursing time. However, it must be emphasised that the
pharmacoeconomic data to confirm these potential benefits
are not currently available, and given the cost differential
between intravenous formulations of PPIs and H2RAs,
studies to define the overall cost effectiveness of PPIs in
critical care should be a further avenue of future research.
In a clinical situation in which most patients may have renal
and/or hepatic dysfunction and require multiple drug
treatment, differences between PPIs in terms of pharmaco-
kinetics and the potential for drug interactions may be of
significant importance. Pantoprazole can be used without
dose adjustment in patients with organ dysfunction and has a
low potential for drug interactions, and therefore among the
currently available agents it may have advantages in stress
ulcer prophylaxis for certain patient groups in the ICU setting.
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